Nemdatine

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

memantine

Available from:

Actavis Group PTC ehf.

ATC code:

N06DX01

INN (International Name):

memantine

Therapeutic group:

Psychoanaleptics, , Oħra kontra d-dimenzja id-drogi

Therapeutic area:

Marda ta 'Alzheimer

Therapeutic indications:

Trattament ta 'pazjenti b'mard ta' Alzheimer moderat għal sever.

Product summary:

Revision: 13

Authorization status:

Awtorizzat

Authorization date:

2013-04-22

Patient Information leaflet

                                71
B. FULJETT TA’ TAGĦRIF
72
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
NEMDATINE 5 MG PILLOLI MIKSIJIN B’RITA
memantine hydrochloride
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib jew lill-ispiżjar
tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anki jekk ikollhom l-istess sinjali ta’
mardmard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li m’huwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1
X’inhu Nemdatine u għalxiex jintuża
2
X’għandek tkun taf qabelq ma tieħu Nemdatine
3
Kif għandek tieħu Nemdatine
4
Effetti sekondarji li jista’ jkollu
5
Kif taħżen Nemdatine
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU NEMDATINE U GĦALXIEX JINTUŻAJINTUŻA
KIF JAĦDEM NEMDATINE
Nemdatine fih is-sustanza attiva memantine hydrochloride. Nemdatine
jagħmel parti minn grupp ta’
mediċini magħrufa bħala mediċini kontra d-dimenzja.
It-telf tal-memorja fil-marda ta’ Alzheimer jiġi minħabba disturbi
fis-sinjali tal-messaġġi fil-moħħ.
Il-moħħ fih l-hekk imsejjħa riċetturi-N-mthyl D-aspartate (NMDA)
li jieħdu sehem fit-trasmissjoni
tas-sinjali fin-nervituri importanti għat-tagħlim u l-memorja.
Nemdatine jagħmel parti minn grupp ta’
mediċini li jissejħu antagonisti tar-riċettur-NMDA. Nemdatine
jaħdem fuq dawn ir-riċetturi-NMDA u
jtejjeb it-trasmissjoni tas-sinjali fin-nervituri u l-memorja.
GĦALXIEX JINTUŻA NEMDATINE
Nemdatine jintuża għall-kura ta’ pazjenti adulti bil-marda ta’
Alzheimer minn moderata għal severa.
2.
X’GĦANDEK TKUN TAF QABEL MA TIEĦU NEMDATINE
TIEĦUX NEMDATINE
-
jekk inti allerġiku/a għal memantine hydrochloride jew sustanzi
oħra ta’ din il- m
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM TAL-PRODOTT MEDIĊINALI
Nemdatine 5 mg pilloli miksija b’rita
Nemdatine 10 mg pilloli miksija b’rita
Nemdatine 15 mg pilloli miksija b’rita
Nemdatine 20 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
_ _
Nemdatine 5 mg
Kull pillola miksija b’rita fiha 5 mg memantine hydrochloride
ekwivalenti għal 4.15 mg memantine.
Nemdatine 10 mg
Kull pillola miksija b’rita fiha 10 mg memantine hydrochloride
ekwivalenti għal 8.31 mg memantine.
Nemdatine 15 mg
Kull pillola miksija b’rita fiha 15 mg memantine hydrochloride
ekwivalenti għal 12.46 mg memantine.
Nemdatine 20 mg
Kull pillola miksija b’rita fiha 20 mg memantine hydrochloride
ekwivalenti għal 16.62 mg memantine.
Eċċipjent (i) b'effett magħruf:
Nemdatine 5 mg pilloli miksija b’rita
Kull pillola miksija b'rita fiha 0.47 mg lactose monohydrate.
Nemdatine 10 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 0.95 mg lactose monohydrate.
Nemdatine 15 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 1.42 mg lactose monohydrate.
Nemdatine 20 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 1.89 mg lactose monohydrate.
Għal-lista kompleta ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita.
Nemdatine 5 mg pilloli miksija b’rita
Il-pillola miksija b’rita ta’ 5 mg hija bajda, f’għamla ovali
ta’ daqs ta’ 8 mm x 4.5 mm, b’marka ta’
‘M5’ fuq naħa waħda.
3
Nemdatine 10 mg pilloli miksija b’rita
Pillola miksija b’rita, bajda, għamla ta’ kapsula, ibbuzzata fuq
iż-żewġ naħat, b’daqs ta’
9.8 mm x 4.9 mm, b’sinjal imnaqqax u l-marka “M 10” imnaqqxa fuq
in-naħa fejn hemm is-sinjal
imnaqqax.
Il-pillola tista’ tinqasam f’dożi ndaqs.
Nemdatine 15 mg pilloli miksija b’rita
Pillola miksija b’rita, oranġjo, għamla ovali, ibbuzzata fuq
iż-żewġ naħat, b’daqs ta’
11.4 mm x 6.4 mm, bil-marka “M15” imnaqqxa fuq naħa waħda.
Nemdatine 20 mg pilloli miksi
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 17-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 17-01-2024
Public Assessment Report Public Assessment Report Bulgarian 30-04-2013
Patient Information leaflet Patient Information leaflet Spanish 17-01-2024
Public Assessment Report Public Assessment Report Spanish 30-04-2013
Patient Information leaflet Patient Information leaflet Czech 17-01-2024
Public Assessment Report Public Assessment Report Czech 30-04-2013
Patient Information leaflet Patient Information leaflet Danish 17-01-2024
Public Assessment Report Public Assessment Report Danish 30-04-2013
Patient Information leaflet Patient Information leaflet German 17-01-2024
Public Assessment Report Public Assessment Report German 30-04-2013
Patient Information leaflet Patient Information leaflet Estonian 17-01-2024
Public Assessment Report Public Assessment Report Estonian 30-04-2013
Patient Information leaflet Patient Information leaflet Greek 17-01-2024
Public Assessment Report Public Assessment Report Greek 30-04-2013
Patient Information leaflet Patient Information leaflet English 17-01-2024
Public Assessment Report Public Assessment Report English 30-04-2013
Patient Information leaflet Patient Information leaflet French 17-01-2024
Public Assessment Report Public Assessment Report French 30-04-2013
Patient Information leaflet Patient Information leaflet Italian 17-01-2024
Public Assessment Report Public Assessment Report Italian 30-04-2013
Patient Information leaflet Patient Information leaflet Latvian 17-01-2024
Public Assessment Report Public Assessment Report Latvian 30-04-2013
Patient Information leaflet Patient Information leaflet Lithuanian 17-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-01-2024
Public Assessment Report Public Assessment Report Lithuanian 30-04-2013
Patient Information leaflet Patient Information leaflet Hungarian 17-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 17-01-2024
Public Assessment Report Public Assessment Report Hungarian 30-04-2013
Patient Information leaflet Patient Information leaflet Dutch 17-01-2024
Public Assessment Report Public Assessment Report Dutch 30-04-2013
Patient Information leaflet Patient Information leaflet Polish 17-01-2024
Public Assessment Report Public Assessment Report Polish 30-04-2013
Patient Information leaflet Patient Information leaflet Portuguese 17-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 17-01-2024
Public Assessment Report Public Assessment Report Portuguese 30-04-2013
Patient Information leaflet Patient Information leaflet Romanian 17-01-2024
Public Assessment Report Public Assessment Report Romanian 30-04-2013
Patient Information leaflet Patient Information leaflet Slovak 17-01-2024
Public Assessment Report Public Assessment Report Slovak 30-04-2013
Patient Information leaflet Patient Information leaflet Slovenian 17-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 17-01-2024
Public Assessment Report Public Assessment Report Slovenian 30-04-2013
Patient Information leaflet Patient Information leaflet Finnish 17-01-2024
Public Assessment Report Public Assessment Report Finnish 30-04-2013
Patient Information leaflet Patient Information leaflet Swedish 17-01-2024
Public Assessment Report Public Assessment Report Swedish 30-04-2013
Patient Information leaflet Patient Information leaflet Norwegian 17-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 17-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 17-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 17-01-2024
Patient Information leaflet Patient Information leaflet Croatian 17-01-2024

Search alerts related to this product

View documents history